Advertisement
Singapore markets close in 4 hours 45 minutes

  • Straits Times Index

    3,301.45
    +8.52 (+0.26%)
     

  • Nikkei

    38,236.07
    -38.03 (-0.10%)
     

  • Hang Seng

    18,466.91
    -9.01 (-0.05%)
     

  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     

  • Bitcoin USD

    63,832.16
    +517.30 (+0.82%)
     

  • CMC Crypto 200

    1,328.48
    +51.50 (+4.03%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • Dow

    38,675.68
    +449.98 (+1.18%)
     

  • Nasdaq

    16,156.33
    +315.33 (+1.99%)
     

  • Gold

    2,317.40
    +8.80 (+0.38%)
     

  • Crude Oil

    78.38
    +0.27 (+0.35%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • FTSE Bursa Malaysia

    1,594.92
    +5.33 (+0.34%)
     

  • Jakarta Composite Index

    7,154.02
    +19.30 (+0.27%)
     

  • PSE Index

    6,677.33
    +61.78 (+0.93%)
     

SHL Telemedicine Full Year 2023 Earnings: US$0.43 loss per share (vs US$0.005 loss in FY 2022)

editorial-team@simplywallst.com (Simply Wall St)
·1-min read

SHL Telemedicine (VTX:SHLTN) Full Year 2023 Results

Key Financial Results

  • Revenue: US$57.1m (down 3.3% from FY 2022).

  • Net loss: US$7.06m (loss widened by US$6.98m from FY 2022).

  • US$0.43 loss per share (further deteriorated from US$0.005 loss in FY 2022).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

SHL Telemedicine Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Healthcare industry in Europe.

Performance of the market in Switzerland.

The company's shares are down 10% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 2 warning signs for SHL Telemedicine (1 is significant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.